文献速递肿瘤 PET/CT核素与放射性配体治疗

99mTc-EDDA/HYNIC-Tyr3-奥曲肽(Tektrotyd)显像意外检出骨骼肌肾细胞癌转移

Unexpected Detection of Skeletal Muscle Renal Cell Carcinoma Metastasis With 99m Tc-EDDA/HYNIC-Tyr3-Octreotide (Tektrotyd) Scan.
PubMed 文献 · Clin Nucl Med · 2022-05-27

本文报道一例70岁男性,有手术切除肾细胞癌病史,因评估胰尾病变行99mTc-Tektrotyd生长抑素受体显像,意外发现左侧颈夹肌病灶呈强烈示踪剂摄取,活检证实为转移性肾细胞癌。

要点

  • 肾细胞癌可表达生长抑素受体,生长抑素受体显像可检出其转移灶。
  • 本例99mTc-Tektrotyd显像意外发现左侧颈夹肌强烈摄取,活检证实为肾细胞癌转移。
  • 生长抑素受体显像用于神经内分泌肿瘤评估时,也可能意外发现肾细胞癌转移。

核心结论

  • 99mTc-Tektrotyd生长抑素受体显像在评估胰尾病变时意外发现左侧颈夹肌病灶呈强烈示踪剂摄取,活检证实为转移性肾细胞癌。

研究设计与样本

  • 个案报道:1例70岁男性,有手术切除肾细胞癌病史,因评估胰尾病变行99mTc-Tektrotyd生长抑素受体显像。

主要发现

  • 显像显示左侧颈夹肌病灶呈强烈示踪剂摄取,该病灶活检结果符合转移性肾细胞癌。
  • 既往个案报道显示,肾细胞癌转移灶可通过奥曲肽显像(Octreoscan)和68Ga-DOTATATE PET/CT等生长抑素受体显像识别。
  • 淋巴瘤、乳腺癌和肾细胞癌等不同肿瘤类型中已显示生长抑素受体过表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Somatostatin receptor scintigraphy with 99m Tc-Tektrotyd is widely used for the investigation of neuroendocrine tumors. Overexpression of somatostatin receptors has been shown in different tumor types including lymphomas, breast carcinoma, and renal cell carcinoma (RCC). Isolated case reports have shown that RCC metastases can be identified using somatostatin receptor imaging such as Octreoscan scintigraphy and 68 Ga-DOTATATE PET/CT. We report the case of a 70-year-old man with a history of surgically removed RCC who referred to 99m Tc-Tektrotyd scintigraphy for the evaluation of a pancreatic tail lesion. The scan revealed intense tracer uptake in a left splenius cervicis muscle lesion that on biopsy was consistent with metastatic RCC.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fuoco V, Barisella M, Lorenzoni A, et al. Unexpected Detection of Skeletal Muscle Renal Cell Carcinoma Metastasis With 99m Tc-EDDA/HYNIC-Tyr3-Octreotide (Tektrotyd) Scan. Clin Nucl Med. 2022. PMID: 35619201. doi:10.1097/RLU.0000000000004302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。